Eliem Therapeutics(US:ELYM)2026-03-05 12:10Financial Performance - Climb Bio reported cash, cash equivalents, and marketable securities of $160.7 million as of December 31, 2025, expected to fund operations into 2028[11] - Research and Development (R&D) expenses for Q4 2025 were $13.7 million, up from $6.0 million in Q4 2024, and total R&D expenses for the full year 2025 were $46.7 million, compared to $14.3 million in 2024[11] - General and Administrative (G&A) expenses for Q4 2025 were $5.6 million, compared to $5.0 million in Q4 2024, with total G&A expenses for the full year 2025 at $21.2 million, up from $16.0 million in 2024[11] - Climb Bio's net loss for Q4 2025 was $17.5 million, compared to a net loss of $8.4 million in Q4 2024, with a total net loss for the full year 2025 of $59.9 million, down from $73.9 million in 2024[11] Clinical Development - The company has three ongoing clinical trials for budoprutug, with initial data from these trials expected in H2 2026[3] - Dosing has been completed in a Phase 1 study of a subcutaneous formulation of budoprutug, with data anticipated in H1 2026[1] - Climb Bio is advancing the clinical development of CLYM116, with initial data from a Phase 1 healthy volunteer study expected in mid-2026[6] - The company published long-term outcome data from the Phase 1b trial of budoprutug in pMN at the 2025 ASN Kidney Week, demonstrating long-term control of proteinuria[4] - Climb Bio received Investigational New Drug (IND) clearance in China for a separate Phase 1b trial in systemic lupus erythematosus (SLE), with the first patient expected to be dosed in H1 2026[5] - Climb Bio's strategic focus includes advancing its pipeline and evaluating budoprutug across multiple indications with high unmet need[3]